ProCE Banner Activity

Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC: Downloadable Slides

Slideset Download

Download this slideset to review the latest data on neoadjuvant treatment and future considerations for patients with HR+/HER2- early breast cancer.

Released: May 12, 2021

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios, Arvinas, AstraZeneca, Bayer, BeyondSpring, BioNTech, Blueprint Medicines, Bristol Myers Squibb/Systimmune, Circle Pharma, Cullinan, CytomX, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui, Incyte, Jazz, Johnson & Johnson/AMBRX, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Tango, Umoja Biopharma, Zentalis, Zuellig, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb/Systimmune, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi, Seattle Genetics.